Fluphenazine decanoate overdose

Patient education
• Inform patient that drug may cause dizziness or drowsiness. Advise patient to avoid hazardous tasks that require alertness until CNS response to drug is established.
• Tell patient to avoid ingestion of alcohol and to seek medical approval before taking other drugs.
• Instruct patient to promptly report rash or hives, anxiety, nervousness, anorexia (especially in underweight patients), suspicion of pregnancy, or intent to become pregnant.

Decanoic acid acts as a non-competitive AMPA receptor antagonist at therapeutically relevant concentrations, in a voltage- and subunit-dependent manner, and this is sufficient to explain its antiseizure effects. [13] This direct inhibition of excitatory neurotransmission by decanoic acid in the brain contributes to the anticonvulsant effect of the MCT ketogenic diet . [13] Decanoic acid and the AMPA receptor antagonist drug perampanel act at separate sites on the AMPA receptor, and so it is possible that they have a cooperative effect at the AMPA receptor, suggesting that perampanel and the ketogenic diet could be synergistic. [13]

Fluphenazine is contraindicated in patients with hematological disease. Hematologic effects including leukopenia, neutropenia, and agranulocytosis have been associated with antipsychotic use. A history of drug-induced leukopenia or neutropenia or pre-existing low white blood cell (WBC) count may increase the likelihood of developing hematologic effects during treatment with an antipsychotic medication. Patients with a history of clinically significant low WBC count or drug-induced leukopenia/neutropenia should have frequent complete blood count (CBC) assessments during the first few months of treatment. Discontinuation of the antipsychotic should be considered if a clinically significant decline in WBC occurs in the absence of an identifiable cause. Patients with clinically significant neutropenia should be closely monitored for fever and infection, and appropriate medical intervention should be instituted if necessary. Fluphenazine should be discontinued in patients with severe neutropenia (ANC < 1000/mm3); ongoing medical care is recommended until the symptoms resolve. Patients with bone marrow suppression secondary to phenothiazine use should not be re-exposed to phenothiazine treatment.

Fluphenazine decanoate overdose

fluphenazine decanoate overdose


fluphenazine decanoate overdosefluphenazine decanoate overdosefluphenazine decanoate overdosefluphenazine decanoate overdosefluphenazine decanoate overdose